{"title": "[Towards COVID-19 control through vaccination: obstacles, challenges and opportunities. SESPAS Report 2022] - PubMed", "author": "Username", "url": "https://pubmed.ncbi.nlm.nih.gov/35781154/", "hostname": "ncbi.nlm.nih.gov", "description": "In Spain, the vaccination program began in a context of high transmission and low availability of vaccines. The objective of this article is to review the vaccination program against COVID-19 in Europe (3/03/2022) and assess the obstacles, challenges and opportunities posed by the control of this di \u2026", "sitename": "PubMed", "date": "2022-08-25", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "[Towards COVID-19 control through vaccination: obstacles, challenges and opportunities. SESPAS Report 2022]\n- PMID: 35781154\n-\nPMCID:\n[PMC9244662](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9244662/)\n-\nDOI:\n[10.1016/j.gaceta.2022.03.002](https://doi.org/10.1016/j.gaceta.2022.03.002)\n[Towards COVID-19 control through vaccination: obstacles, challenges and opportunities. SESPAS Report 2022]\nAbstract\nIn Spain, the vaccination program began in a context of high transmission and low availability of vaccines. The objective of this article is to review the vaccination program against COVID-19 in Europe (3/03/2022) and assess the obstacles, challenges and opportunities posed by the control of this disease. Five vaccines are currently available in Europe: two based on mRNA technology (Comirnaty\u00ae and Spikevax\u00ae); two based on a non-replicative vector (Vaxzevria\u00ae and Janssen); and another based on subunit S (Novavax\u00ae). Health authorities have developed comprehensive vaccination strategies prioritizing the prevention of hospitalizations and deaths. In January 2022, 90% of the population was exceeded with full vaccination and 95% coverage in people over 50 years of age. The new challenge is to achieve similar coverage in the rest of the age groups. Vaccination in children and adolescents has become a priority due to the educational and social implications derived from COVID-19 in this population. Communication strategies must be renewed and access barriers eliminated to achieve good coverage. In Spain, studies have been published that find a high effectiveness of vaccination. The main strategy for controlling the pandemic and recovering social activity is the vaccination, but everything indicates that very high levels of vaccination coverage will be necessary and to follow with the non-pharmaceutical measures. In a globalized world, COVID-19 control will only be achieved with a coordinated global strategy and technical and economic support for the vaccination strategy in resource-poor countries.\nEn Espa\u00f1a se inici\u00f3 el programa de vacunaci\u00f3n en un contexto de alta transmisi\u00f3n y baja disponibilidad de vacunas. El objetivo de este art\u00edculo es revisar el programa de vacunaci\u00f3n frente a la COVID-19 (3-3-2022) y valorar los obst\u00e1culos, los desaf\u00edos y las oportunidades que plantea el control de esta enfermedad. Se dispone actualmente de cinco vacunas: dos basadas en la tecnolog\u00eda ARNm (Comirnaty\u00ae y Spikevax\u00ae), dos basadas en un vector no replicativo (Vaxzevria\u00ae y Janssen) y una basada en la subunidad S (Novavax\u00ae). Las autoridades sanitarias han desarrollado estrategias de vacunaci\u00f3n priorizando la prevenci\u00f3n de hospitalizaciones y defunciones. En marzo de 2022 se super\u00f3 el 90% de la poblaci\u00f3n diana con vacunaci\u00f3n completa y el 95% de cobertura en mayores de 50 a\u00f1os. El nuevo reto es conseguir coberturas similares para una tercera dosis. La vacunaci\u00f3n en la infancia y la adolescencia se ha convertido en una prioridad por las implicaciones educativas y sociales que comporta la COVID-19. Se deber\u00e1n renovar las estrategias comunicativas y eliminar las barreras de acceso para conseguir buenas coberturas. En Espa\u00f1a se han publicado estudios que muestran una alta efectividad de la vacunaci\u00f3n. La principal estrategia para el control de la pandemia y para recuperar la actividad social es la vacunaci\u00f3n, pero todo indica que ser\u00e1n necesarios niveles muy altos de cobertura vacunal y seguir con medidas no farmacol\u00f3gicas. En un mundo globalizado, el control de la COVID-19 solo se alcanzar\u00e1 con una estrategia global coordinada y el apoyo a la vacunaci\u00f3n en los pa\u00edses con pocos recursos.\nKeywords: COVID-19; Epidemiology; Epidemiolog\u00eda; Evaluaci\u00f3n; Evaluation study; SARS-CoV-2; Vaccines; Vacunas.\nCopyright \u00a9 2022 SESPAS. Publicado por Elsevier Espa\u00f1a, S.L.U. All rights reserved.\nSimilar articles\n-\n[[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].](/36274602/)Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1356-1386. doi: 10.3760/cma.j.cn112150-20220825-00840. Zhonghua Yu Fang Yi Xue Za Zhi. 2022. PMID: 36274602 Chinese.\n-\n[Influenza vaccination strategies for 2020-21 in the context of COVID-19.](/33312512/)J Glob Health. 2020 Dec;10(2):021102. doi: 10.7189/jogh.10.021102. J Glob Health. 2020. PMID: 33312512 Free PMC article.\n-\n[Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.](/33317870/)Vaccine. 2021 Jan 8;39(2):255-262. doi: 10.1016/j.vaccine.2020.12.010. Epub 2020 Dec 13. Vaccine. 2021. PMID: 33317870 Free PMC article.\n-\n[The COVID-19 Vaccination program and barriers of vaccination: \u0430 Review and comparison. Evidence from Iran and Russia.](/35670387/)Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2022 May;30(3):356-363. doi: 10.32687/0869-866X-2022-30-3-356-363. Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2022. PMID: 35670387 Review.\n-\n[Update on COVID-19 and Effectiveness of a Vaccination Campaign in a Global Context.](/36078427/)Int J Environ Res Public Health. 2022 Aug 28;19(17):10712. doi: 10.3390/ijerph191710712. Int J Environ Res Public Health. 2022. PMID: 36078427 Free PMC article. Review.\nCited by\n-\n[[Public Health and Health Administration in the COVID-19 pandemic. SESPAS Report 2022].](/35781140/)Gac Sanit. 2022;36 Suppl 1:S1-S3. doi: 10.1016/j.gaceta.2022.05.002. Epub 2022 May 24. Gac Sanit. 2022. PMID: 35781140 Free PMC article. Review. Spanish. No abstract available.\nReferences\n-\n-\nThe Financial Times. Covid vaccine development: the shots available and the doses administered. The Financial Times; 2021. (Consultado el 20-11-2021.) Disponible en:\n[https://www.ft.com/content/ac5e5ef8-bccb-482b-9f8d-0dab5cac6f9a](https://www.ft.com/content/ac5e5ef8-bccb-482b-9f8d-0dab5cac6f9a)].\n- The Financial Times. Covid vaccine development: the shots available and the doses administered. The Financial Times; 2021. (Consultado el 20-11-2021.) Disponible en:\n-\n-\nKatz I.T., Weintraub R., Bekker L.G., et al. From vaccine nationalism to vaccine equity \u2014 finding a path forward. N Engl J Med. 2021;384:1281\u20131283.\n-\n[PubMed](/33830709/)\n- Katz I.T., Weintraub R., Bekker L.G., et al. From vaccine nationalism to vaccine equity \u2014 finding a path forward. N Engl J Med. 2021;384:1281\u20131283. -\n-\n-\n-\n-\nGrupo de trabajo t\u00e9cnico de vacunaci\u00f3n COVID-19 de la Ponencia de Programa y Registro de Vacunaciones. Actualizaci\u00f3n 6. Estrategia de vacunaci\u00f3n frente a COVID-19 en Espa\u00f1a. Madrid: Ministerio de Sanidad, Gobierno de Espa\u00f1a; 2021. p. 1-26. Disponible en:\n[https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacuna...](https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion8_EstrategiaVacunacion.pdf).\n- Grupo de trabajo t\u00e9cnico de vacunaci\u00f3n COVID-19 de la Ponencia de Programa y Registro de Vacunaciones. Actualizaci\u00f3n 6. Estrategia de vacunaci\u00f3n frente a COVID-19 en Espa\u00f1a. Madrid: Ministerio de Sanidad, Gobierno de Espa\u00f1a; 2021. p. 1-26. Disponible en:\nPublication types\nMeSH terms\nSubstances\nLinkOut - more resources\nFull Text Sources\nMedical\nMiscellaneous", "language": null, "image": "https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png", "pagetype": "website", "links": ["#article-details", "https://www.ncbi.nlm.nih.gov/", "https://account.ncbi.nlm.nih.gov", "/myncbi/", "/myncbi/collections/bibliography/", "/account/settings/", "/account/signout/", "https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys", "https://www.ncbi.nlm.nih.gov", "/myncbi/", "#maincontent", "#", null, "/", "#", "#", "/advanced/", "/clipboard/", "/help/", "#", "https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35781154%2F%23open-bibliography-panel", "https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35781154%2F%23open-collections-panel", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/account/settings/", "http://www.elsevier.es/en/linksolver/ft/pii/S0213-9111(22)00098-X", "https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35781154/", "#", "#", "http://twitter.com/intent/tweet?text=%5BTowards%20COVID-19%20control%20through%20vaccination%3A%20obstacles%2C%20challenges%20and%20opportunities.%20SESPAS%20Report%202022%5D%20https%3A//pubmed.ncbi.nlm.nih.gov/35781154/", "http://www.facebook.com/sharer/sharer.php?u=https%3A//pubmed.ncbi.nlm.nih.gov/35781154/", "#heading", "#abstract", "#similar", "#citedby", "#references", "#publication-types", "#mesh-terms", "#substances", "#linkout", "/?term=%22Gac+Sanit%22%5Bjour%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Gac+Sanit%22%5BTitle+Abbreviation%5D", "#", "/?term=Godoy+P&cauthor_id=35781154", "#full-view-affiliation-1", "/?term=Castilla+J&cauthor_id=35781154", "#full-view-affiliation-2", "/?term=Astray+J&cauthor_id=35781154", "#full-view-affiliation-3", "/?term=Godoy+S&cauthor_id=35781154", "#full-view-affiliation-4", "/?term=Tuells+J&cauthor_id=35781154", "#full-view-affiliation-5", "/?term=Barrabeig+I&cauthor_id=35781154", "#full-view-affiliation-6", "/?term=Dom%C3%ADnguez+%C3%81&cauthor_id=35781154", "#full-view-affiliation-7", "http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9244662/", "https://doi.org/10.1016/j.gaceta.2022.03.002", "/?term=%22Gac+Sanit%22%5Bjour%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Gac+Sanit%22%5BTitle+Abbreviation%5D", "#", "/?term=Godoy+P&cauthor_id=35781154", "#short-view-affiliation-1", "/?term=Castilla+J&cauthor_id=35781154", "#short-view-affiliation-2", "/?term=Astray+J&cauthor_id=35781154", "#short-view-affiliation-3", "/?term=Godoy+S&cauthor_id=35781154", "#short-view-affiliation-4", "/?term=Tuells+J&cauthor_id=35781154", "#short-view-affiliation-5", "/?term=Barrabeig+I&cauthor_id=35781154", "#short-view-affiliation-6", "/?term=Dom%C3%ADnguez+%C3%81&cauthor_id=35781154", "#short-view-affiliation-7", "http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9244662/", "https://doi.org/10.1016/j.gaceta.2022.03.002", "#eng-abstract", "#spa-abstract", "/36274602/", "/33312512/", "/33317870/", "/35670387/", "/36078427/", null, "/35781140/", "https://www.ft.com/content/ac5e5ef8-bccb-482b-9f8d-0dab5cac6f9a", "/33830709/", "http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8014072/", "/33650737/", "http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8494620/", "/34147145/", "https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion8_EstrategiaVacunacion.pdf", "/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Review", "#", "/?term=%22Adolescent%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Adolescent", "#", "/?term=%22COVID-19%2Fepidemiology%22%5BMAJR%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=COVID-19", "#", "/?term=%22COVID-19%2Fprevention+and+control%22%5BMAJR%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=COVID-19", "#", "/?term=%22Child%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Child", "#", "/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Humans", "#", "/?term=%22Immunization+Programs%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Immunization+Programs", "#", "/?term=%22Influenza+Vaccines%22%5BMAJR%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Influenza+Vaccines", "#", "/?term=%22Middle+Aged%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Middle+Aged", "#", "/?term=%22Pandemics%2Fprevention+and+control%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Pandemics", "#", "/?term=%22Vaccination%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Vaccination", "#", "/?term=%22Influenza+Vaccines%22%5Bnm%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=%22Influenza+Vaccines%22", "#", "http://www.elsevier.es/en/linksolver/ft/pii/S0213-9111(22)00098-X", "https://linkinghub.elsevier.com/retrieve/pii/S0213-9111(22)00098-X", "https://europepmc.org/abstract/MED/35781154", "https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35781154/", "https://medlineplus.gov/flushot.html", "https://assays.cancer.gov/CPTAC-438", "http://www.elsevier.es/en/linksolver/ft/pii/S0213-9111(22)00098-X", "https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35781154/", "#", "#", "#", "https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35781154%2F%23open-bibliography-panel", "https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35781154%2F%23open-collections-panel", "#", "https://www.ncbi.nlm.nih.gov/mesh/", "https://www.ncbi.nlm.nih.gov/pmc/", "https://www.ncbi.nlm.nih.gov/books", "/disclaimer/", "https://twitter.com/ncbi", "https://www.facebook.com/ncbi.nlm", "https://www.linkedin.com/company/ncbinlm", "https://github.com/ncbi", "https://ncbiinsights.ncbi.nlm.nih.gov/", "https://www.nlm.nih.gov/socialmedia/index.html", "https://twitter.com/NLM_NIH", "https://www.facebook.com/nationallibraryofmedicine", "https://www.youtube.com/user/NLMNIH", "https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323", "https://www.nlm.nih.gov/web_policies.html", "https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office", "https://www.hhs.gov/vulnerability-disclosure-policy/index.html", "https://support.nlm.nih.gov/", "https://www.nlm.nih.gov/accessibility.html", "https://www.nlm.nih.gov/careers/careers.html", "//www.nlm.nih.gov/", "https://www.nih.gov/", "https://www.hhs.gov/", "https://www.usa.gov/"]}